Zydus Animal Health and Investments Ltd has a leadership position across a wide spectrum of therapeutic and nutritional products for livestock and poultry animal segments
Pharmaceutical major Zydus Cadila said on Wednesday it has signed agreements to sell one of its animal health business companies to Multiples Alternate Asset Management led consortium for Rs 2,921 crore.
The consortium includes Canada Pension Plan Investment Board and RARE Enterprises. The slump sale transaction is expected to be complete within 90 days. Zydus Animal Health and Investments Ltd (ZAHL) has a leadership position across a wide spectrum of therapeutic and nutritional products for livestock and poultry animal segments. It employs 700 people and has one manufacturing facility in Haridwar.
The transaction to sell one of the two business undertakings of ZAHL involves the transfer of immovable assets, movable assets, inventory, brands and intangible assets, contracts, licenses and permissions, business records, employees along employee benefit funds, insurance policies, other assets, and assumed liabilities.
“The Zydus AH business has a very strong franchise in the market and is extremely well-positioned to take advantage of the continued industry growth in India and select export markets,” said Managing Director Arun Atrey.
“We expect this process to be seamless for our customers, suppliers, and other stakeholders with no disruption to our operations,” he said in a statement.
ZAHL has another animal healthcare business undertaking that is expected to start operations in the United States and certain European countries.